134 related articles for article (PubMed ID: 35491212)
21. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
Olariu TR; Ursoniu S; Marincu I; Lupu MA
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
[No Abstract] [Full Text] [Related]
23. The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
Gueguen M; Khatchatourian L; Lohéac C; Dorval I; Mercier M; Le Calloch R; Mahé K; Rizcallah MJ; Hutin P; Fangous MS; Saidani N; Le Clech L
Infect Dis Now; 2022 Aug; 52(5):280-285. PubMed ID: 35667558
[TBL] [Abstract][Full Text] [Related]
24. Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids.
Ishii N; Hatakeyama S; Yoneyama T; Tanaka R; Narita T; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
Urol Oncol; 2022 Oct; 40(10):451.e1-451.e8. PubMed ID: 36008254
[TBL] [Abstract][Full Text] [Related]
25. Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM; Nelli F; Fabbri A; Onorato A; Giannarelli D; Giron Berrios JR; Virtuoso A; Marrucci E; Mazzotta M; Schirripa M; Panichi V; Pessina G; Signorelli C; Chilelli MG; Primi F; Natoni F; Fazio S; Silvestri MA
ESMO Open; 2022 Feb; 7(1):100350. PubMed ID: 34942438
[TBL] [Abstract][Full Text] [Related]
26. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
27. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
[TBL] [Abstract][Full Text] [Related]
28. Antigen-Specific CD4
Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
Front Immunol; 2022; 13():827048. PubMed ID: 35237272
[TBL] [Abstract][Full Text] [Related]
29. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients.
Ligumsky H; Safadi E; Etan T; Vaknin N; Waller M; Croll A; Nikolaevski-Berlin A; Greenberg I; Halperin T; Wasserman A; Galazan L; Arber N; Wolf I
J Natl Cancer Inst; 2022 Feb; 114(2):203-209. PubMed ID: 34453830
[TBL] [Abstract][Full Text] [Related]
32. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
33. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
35. Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up.
Matusali G; Sberna G; Meschi S; Gramigna G; Colavita F; Lapa D; Francalancia M; Bettini A; Capobianchi MR; Puro V; Castilletti C; Vaia F; Bordi L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215903
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.
Massarweh A; Tschernichovsky R; Stemmer A; Benouaich-Amiel A; Siegal T; Eliakim-Raz N; Stemmer SM; Yust-Katz S
J Neurooncol; 2022 Feb; 156(3):483-489. PubMed ID: 35018613
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
38. Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient.
Hagihara M; Imai Y; Uchida T; Ohara S; Inoue M; Sugi T; Mitamura K
Intern Med; 2022; 61(14):2215-2219. PubMed ID: 35850990
[TBL] [Abstract][Full Text] [Related]
39. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine.
Yamamoto S; Mizoue T; Tanaka A; Oshiro Y; Inamura N; Konishi M; Ozeki M; Miyo K; Sugiura W; Sugiyama H; Ohmagari N
Obesity (Silver Spring); 2022 May; 30(5):999-1003. PubMed ID: 35226399
[TBL] [Abstract][Full Text] [Related]
40. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
